August 14, 2019 -
photonamic GmbH & Co. KG (Head office: Pinneberg, Germany; CEO: Ulrich Kosciessa, Ph.D.) (“photonamic”), a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku,Tokyo; Representative Director, President and CEO: Yoshitaka Kitao) is engaged in the business of pharmaceutical development of 5-aminolevulinic acid (“5-ALA”) (*) hereby announces the acquisition of the
… Read MoreAugust 14, 2018 -MolecuLight Inc. achieved a major regulatory milestone permitting expansion into the United States market. FDA has granted De Novo clearance for the ground-breaking wound fluorescence imaging device, the MolecuLight i:X. Read More
October 17, 2017 -
TORONTO, CANADA. MolecuLight, a global leader in fluorescence image-guidance solutions, is pleased to announce the appointment of industry veteran Anil Amlani as Chief Executive Officer effective September 29, 2017.
William Wignall, Chairman of the Board at MolecuLight, commented, “The Board is delighted to welcome Anil as MolecuLight’s new CEO. Anil
… Read MoreSeptember 16, 2016 -The MolecuLight i:X Imaging Device can instantly visualize potentially harmful bacteria at the point of care
TORONTO – September 16, 2016 – MolecuLight Inc. has received CE Mark approval authorizing commercial sales in the European Union of its MolecuLight i:X Imaging Device, that is revolutionizing wound care.
The MolecuLight i:X will be making
… Read MoreJune 21, 2016 -This premier awards program for the medtech industry announced the 2016 winners
Toronto, June 21, 2016: The Medical Design Excellence Awards (MDEA), the premier awards program for the medtech industry announced the 2016 winners on Tuesday, June 14th at a special ceremony at the MD&M East conference and exposition in
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.